Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

FATE THERAPEUTICS INC Director's Dealing 2014

Jun 12, 2014

34091_dirs_2014-06-12_8bfc6074-7371-4bee-a816-b473602556bf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2014-06-11

Reporting Person: Flynn Peter D (See remarks)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-06-11 Common Stock M 1017 $1.63 Acquired 5056 Direct
2014-06-11 Common Stock S 1017 $7 Disposed 4039 Direct
2014-06-12 Common Stock M 3949 $1.63 Acquired 7988 Direct
2014-06-12 Common Stock M 422 $1.37 Acquired 8410 Direct
2014-06-12 Common Stock M 1100 $1.63 Acquired 9510 Direct
2014-06-12 Common Stock S 5471 $7 Disposed 4039 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-06-11 Stock Option (right to buy) $1.63 M 1017 Disposed 2022-02-08 Common Stock (1017) Direct
2014-06-12 Stock Option (right to buy) $1.63 M 3949 Disposed 2022-02-08 Common Stock (3949) Direct
2014-06-12 Stock Option (right to buy) $1.37 M 422 Disposed 2022-07-23 Common Stock (422) Direct
2014-06-12 Stock Option (right to buy) $1.63 M 1100 Disposed 2022-02-08 Common Stock (1100) Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2013.

F2: The shares subject to this option shall vest and become exercisable at the rate of 1/4th of the shares on May 30, 2012 and 1/48th of the shares each month thereafter such that this option is fully exercisable on May 30, 2015. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.

F3: Not applicable.

F4: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 3, 2012 such that this option is fully exercisable on July 3, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.

F5: The shares subject to this option shall vest and become exercisable in 24 equal monthly installments beginning on the date one month after the completion of the Issuer's initial public offering. This option is subject to accelerated vesting upon a change of control of the Issuer after the completion of the Issuer's initial public offering.